In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models



Authors
Takaaki Oba, Kenichi Makino, Ryutaro Kajihara, Toshihiro Yokoi, Ryoko Araki, Masumi Abe, Hans Minderman, Alfred E. Chang, Kunle Odunsi, and Fumito Ito

Correspondence
fumito.ito@roswellpark.org

In brief
Combination of in situ administration of iPSC-derived dendritic cells (iPSC-DC) and radiotherapy (RT) facilitated the priming of tumor-specific CD8+ T cells, synergistically delayed the growth of not only the treated tumor but also the distant non-irradiated tumors, and rendered poorly immunogenic tumors responsive to anti-PD-L1 therapy along with the development of tumor-specific immunological memory.